Table 1.
Patient demographics and baseline characteristics
| All patients (n = 44) | |
|---|---|
| Follow-up (median and range) | 16 mo (7-52) |
| Age, year | |
| Median (range) | 71 (42-93) |
| Sex, no. (%) | |
| Male | 29 (66) |
| Female | 15 (34) |
| ECOG performance status score, no. (%) | |
| 0 | 12 (27) |
| 1 | 20 (46) |
| 2 | 9 (21) |
| 3 | 2 (5) |
| Location of tumor, no. (%) | |
| Head | 35 (80) |
| Body/tail | 9 (20) |
| Proximity to OARs, no. (%) | |
| Abutting OAR | 35 (80) |
| Invading OAR | 5 (11) |
| No tumor involvement | 4 (9) |
| Resectability at diagnosis, no. (%) | |
| Unresectable | 28 (64) |
| Borderline resectable | 6 (14) |
| Medically inoperable | 10 (23) |
| Neoadjuvant chemotherapy, no. (%) | |
| FOLFIRINOX | 16 (36) |
| Nab-paclitaxel and gemcitabine | 15 (34) |
| Gemcitabine alone | 3 (7) |
| Nab-paclitaxel alone | 2 (4) |
| No neoadjuvant | 8 (18) |
| Radiation modality, no. (%) | |
| Cobalt-60 system | 38 (86) |
| MR-LINAC system | 6 (14) |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; MR-LINAC = magnetic resonance-guided linear accelerator; OAR = organs-at-risk.